Introduction: The Urgency of Early and Accurate Alzheimer’s Detection

Alzheimer’s disease (AD) presents a growing global health challenge, affecting more than 55 million people worldwide—a figure projected to nearly triple by 2050 due to aging populations. In the United States alone, approximately 7.2 million individuals over the age of 65 currently live with AD, with this number expected to rise to nearly 13.8 million by 2060. These figures underscore the critical need for earlier and more accurate diagnostic methods to facilitate timely intervention and improve long-term outcomes.

Conventional diagnostic approaches often rely on subjective cognitive assessments and limited access to advanced imaging technologies, which can result in delayed or inaccurate diagnoses. These limitations hinder effective treatment planning and contribute to the disease’s high societal burden. In this context, artificial intelligence (AI) has emerged as a powerful tool to enhance diagnostic accuracy and speed by detecting complex patterns in neuroimaging and clinical data that are often imperceptible to human evaluators.

Among the latest developments in AI for AD detection, deep ensemble learning and transformer-based models stand out for their capacity to integrate spatial, temporal, and multimodal information with high precision. Ensemble learning leverages the strengths of multiple deep learning architectures to enhance robustness and reduce variance, while transformers, originally developed for natural language processing, are adept at capturing long-range dependencies and sequential trends—making them particularly suited for longitudinal neuroimaging and clinical datasets. This synergy represents a significant leap toward earlier and more personalized diagnosis in AD, aligning with the broader goals of precision medicine.

The Promise of AI in Neurodegenerative Disease Diagnosis

Artificial intelligence has increasingly transformed the landscape of neurodegenerative disease diagnosis, especially through the application of deep learning to neuroimaging data such as magnetic resonance imaging (MRI) and positron emission tomography (PET). Convolutional neural networks (CNNs) have been widely employed for classifying AD-related brain changes, showing strong performance in identifying structural abnormalities and staging disease progression.

Nevertheless, Alzheimer’s diagnosis remains inherently complex due to overlapping symptoms with other forms of dementia, significant interindividual heterogeneity, and the limited availability of well-annotated datasets. These factors can hinder model generalization and affect the reliability of early diagnosis. Transformer-based architectures have begun to address these challenges by incorporating self-attention mechanisms that model both spatial and temporal dependencies within and across imaging slices, allowing for a more holistic analysis of disease progression.

Recent developments have combined transformers with CNNs and recurrent neural networks (RNNs), enhancing the models’ ability to integrate both local and global features. These hybrid systems not only boost diagnostic performance but also provide a framework for explainability—an increasingly important consideration for clinical integration. Many transformer-based models now employ explainable AI (XAI) tools to visualize which regions of the brain or biomarkers are contributing to their predictions, helping to foster trust among clinicians and improving interpretability of the model’s decision-making process.

Case Studies and Recent Breakthroughs

The last few years have seen rapid advances in the use of deep ensemble learning and transformers for Alzheimer’s diagnosis, with models demonstrating exceptional accuracy, particularly in distinguishing mild cognitive impairment (MCI) from early-stage AD. A 2025 study published in PLOS One reported a transformer-based ensemble model integrating MRI and RNA-sequencing data, achieving 98.75% accuracy. This model also incorporated explainable AI components that highlighted key biomarkers such as hippocampal atrophy and temporal lobe degeneration—features well-established in AD pathology.

Another high-performing model combined three widely used CNN architectures—VGG16, MobileNet, and InceptionResNetV2—into a single ensemble, yielding 97.93% accuracy in detecting AD from MRI scans. This architecture demonstrated robustness across various scan types and imaging conditions, offering a promising solution for real-world deployment. In a broader validation effort, a five-model ensemble incorporating VGG16, ResNet50, and EfficientNetB7 achieved 99.32% accuracy on a large, multi-institutional dataset, and maintained strong performance (86.6% and 99.5%) on the external OASIS and ADNI datasets, respectively.

These results highlight not only the diagnostic power of ensemble models but also their ability to generalize across institutions, imaging devices, and patient populations—a key requirement for widespread clinical adoption. The inclusion of transformers within these frameworks further strengthens their capacity to model sequential and multimodal data, enhancing their performance in early-stage detection where subtle changes are often difficult to detect.

Importantly, interpretability remains a focus of model development. Visualization tools such as Grad-CAM and attention heatmaps have been used to identify the regions most influential in driving model predictions. These tools provide clinicians with a visual explanation of AI-generated diagnoses, bridging the gap between computational decision-making and human clinical judgment.

As the field progresses, there is a growing consensus that integrating explainable transformer-based ensemble models into clinical practice can revolutionize AD screening, especially in settings with limited access to expert neurologists or advanced diagnostic equipment. This innovation not only holds the potential to shift diagnosis earlier in the disease course but also supports personalized therapeutic strategies tailored to a patient’s unique progression profile.

Reference:

  1. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025 Apr 29;21(4):e70235. doi: 10.1002/alz.70235. PMCID: PMC12040760.

  2. The global macroeconomic burden of Alzheimer's disease and other dementias: estimates and projections for 152 countries or territories. Chen, Simiao et al. The Lancet Global Health, Volume 12, Issue 9, e1534 - e1543

  3. Wang Y, Sheng H, Wang X. Recognition and diagnosis of Alzheimer's Disease using T1-weighted magnetic resonance imaging via integrating CNN and Swin vision transformer. Clinics (Sao Paulo). 2025 Jun 17;80:100673. doi: 10.1016/j.clinsp.2025.100673. Epub ahead of print. PMID: 40532357; PMCID: PMC12212162.

  4. Anzum H, Sammo NS, Akhter S. Leveraging transformers and explainable AI for Alzheimer's disease interpretability. PLoS One. 2025 May 23;20(5):e0322607. doi: 10.1371/journal.pone.0322607. PMID: 40408321; PMCID: PMC12101688.

  5. Wu Q, Wang Y, Zhang X, Zhang H, Che K. A hybrid transformer-based approach for early detection of Alzheimer's disease using MRI images. Bioimpacts. 2025 Apr 12;15:30849. doi: 10.34172/bi.30849. PMID: 40584904; PMCID: PMC12204811.

  6. Yao Z, Xie W, Chen J, Zhan Y, Wu X, Dai Y, Pei Y, Wang Z, Zhang G. IT: An interpretable transformer model for Alzheimer's disease prediction based on PET/MR images. Neuroimage. 2025 May 1;311:121210. doi: 10.1016/j.neuroimage.2025.121210. Epub 2025 Apr 11. PMID: 40222500.

  7. Alruily M, Abd El-Aziz AA, Mostafa AM, Ezz M, Mostafa E, Alsayat A, El-Ghany SA. Ensemble deep learning for Alzheimer's disease diagnosis using MRI: Integrating features from VGG16, MobileNet, and InceptionResNetV2 models. PLoS One. 2025 Apr 7;20(4):e0318620. doi: 10.1371/journal.pone.0318620. PMID: 40193955; PMCID: PMC11975380.

  8. Jumaili MLF, Sonuç E. ML-Driven Alzheimer's disease prediction: A deep ensemble modeling approach. SLAS Technol. 2025 Jun;32:100298. doi: 10.1016/j.slast.2025.100298. Epub 2025 May 17. PMID: 40389063.

  9. Mujahid M, Rehman A, Alam T, Alamri FS, Fati SM, Saba T. An Efficient Ensemble Approach for Alzheimer’s Disease Detection Using an Adaptive Synthetic Technique and Deep Learning. Diagnostics. 2023; 13(15):2489. https://doi.org/10.3390/diagnostics13152489

  10. Oraby, S., Emran, A., El-Saghir, B. et al. Hybrid of DSR-GAN and CNN for Alzheimer disease detection based on MRI images. Sci Rep 15, 12727 (2025). https://doi.org/10.1038/s41598-025-94677-9